Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Higashi-ku, Hamamatsu, 431-3192, Japan.
Department of Pulmonary Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda, 426-8677, Japan.
Respirology. 2023 Jul;28(7):659-668. doi: 10.1111/resp.14493. Epub 2023 Mar 22.
Interstitial lung disease (ILD) is progressive with high symptom burdens and poor prognosis. Patients with ILD need optimal palliative care to maintain their quality of life, however, few nationwide surveys have addressed palliative care for ILD.
A nationwide, self-administered questionnaire was conducted. Questionnaires were sent by mail to pulmonary specialists certified by the Japanese Respiratory Society (n = 3423). The current practices of PC for ILD, end-of-life communication, referral to a PC team, barriers to PC for ILD, and comparison of PC between ILD and lung cancer (LC).
1332 (38.9%) participants completed the questionnaire, and the data of 1023 participants who had cared for ILD patients in the last year were analysed. Most participants reported that ILD patients often or always complained of dyspnoea and cough, but only 25% had referred them to a PC team. The timing of end-of-life communication tended to be later than the physician-perceived ideal timing. The participants experienced significantly greater difficulty in symptomatic relief and decision-making in PC for ILD compared to LC. Prescription of opioids for dyspnoea was less frequent for ILD than for LC. ILD-specific barriers in PC included an 'inability to predict prognosis', 'lack of established treatments for dyspnoea', 'shortage of psychological and social support', and 'difficulty for patients/families to accept the disease's poor prognosis'.
Pulmonary specialists experienced more difficulty in providing PC for ILD compared to LC and reported considerable ILD-specific barriers in PC. Multifaceted clinical studies are needed to develop optimal PC for ILD.
间质性肺疾病(ILD)呈进行性发展,症状负担重,预后差。ILD 患者需要最佳的姑息治疗来维持生活质量,但很少有全国性调查涉及 ILD 的姑息治疗。
进行了一项全国性的、自我管理的问卷调查。问卷通过邮件发送给日本呼吸学会认证的肺部专家(n=3423)。调查了目前ILD 的姑息治疗实践、临终沟通、向姑息治疗团队转介、ILD 姑息治疗的障碍以及 ILD 和肺癌(LC)之间的姑息治疗比较。
1332 名(38.9%)参与者完成了问卷调查,对过去一年照顾过 ILD 患者的 1023 名参与者的数据进行了分析。大多数参与者报告说,ILD 患者经常或总是抱怨呼吸困难和咳嗽,但只有 25%的患者将他们转介给姑息治疗团队。临终沟通的时间往往晚于医生认为的理想时间。与 LC 相比,参与者在 ILD 的姑息治疗中在症状缓解和决策方面遇到了更大的困难。对于呼吸困难,开具阿片类药物的处方在 ILD 中比在 LC 中更为少见。ILD 姑息治疗中的具体障碍包括“无法预测预后”、“缺乏治疗呼吸困难的既定方法”、“心理和社会支持不足”以及“患者/家属难以接受疾病预后不良”。
与 LC 相比,肺部专家在提供 ILD 的姑息治疗方面遇到了更多的困难,并报告了姑息治疗中相当多的与 ILD 相关的障碍。需要进行多方面的临床研究,以制定针对 ILD 的最佳姑息治疗方案。